2025-04-30 - Analysis Report
## Natera Inc. (NTRA) Stock Report

**0. Key Figures at a Glance:**

* **Cumulative Return (NTRA):** 135.12%
* **Cumulative Return (VOO):** 79.51%
* **Return Difference (NTRA vs VOO):** 55.6%
* **Relative Divergence:** 15.5% (Indicates NTRA's performance is relatively strong compared to its historical range against VOO, but not exceptionally so.)
* **Current Price:** $154.89


**1. Company Overview and Performance Comparison:**

Natera Inc. is a company focused on genetic testing and diagnostics.  Over the period reviewed, NTRA significantly outperformed the S&P 500 (VOO), exhibiting a cumulative return of 135.12% compared to VOO's 79.51%.  This represents a 55.6% difference.  While this is a substantial outperformance, the relative divergence of 15.5% suggests it's within the historically observed range of outperformance, not necessarily an outlier.


**Alpha and Beta Analysis:**

The provided data shows significant volatility in NTRA's performance and varying alpha and beta values across different periods.  High alpha values (e.g., 1.3 in 2017-2019 and 2021-2023) indicate periods of significant outperformance relative to the market, while negative alpha values suggest underperformance.  The beta consistently fluctuates around 1, suggesting varying levels of market sensitivity throughout different periods. Note the large swings in CAGR and MDD (Maximum Drawdown) highlights the risk associated with this investment.


| Year       | CAGR   | MDD    | Alpha | Beta | Cap(B) |
|------------|--------|--------|-------|-------|--------|
| 2015-2017  | -6.0%  | 62.4%  | -0.1  | 1.2   |       |
| 2016-2018  | 29.0%  | 80.1%  | 0.0   | 1.9   |       |
| 2017-2019  | 159.0% | 80.1%  | 1.3   | 4.6   |       |
| 2018-2020  | 530.0% | 80.1%  | 0.7   | 13.5  |       |
| 2019-2021  | 355.0% | 62.9%  | 0.3   | 12.7  |       |
| 2020-2022  | -119.0%| 62.9%  | 0.3   | 5.5   |       |
| 2021-2023  | -482.0%| 69.9%  | 1.3   | 8.5   |       |
| 2022-2024  | -75.0% | 70.6%  | 1.3   | 21.5  |       |
| 2023-2025  | 84.0%  | 72.8%  | 0.9   | 21.1  |       |


**2. Recent Price Movement:**

* **Closing Price:** $154.89
* **5-day Moving Average:** $152.94
* **20-day Moving Average:** $146.01
* **60-day Moving Average:** $152.93

The price is currently above its 5-day and 20-day moving averages, suggesting short-term upward momentum.  However, it's relatively close to its 60-day average, indicating potential consolidation or a minor pullback.  The recent price change of $1.24 is relatively small and doesn't suggest any dramatic event.


**3. Technical Indicators and Expected Return:**

* **Market Risk Indicator (MRI):** 0.379 (Medium Risk)
* **RSI:** 68.26 (Approaching overbought territory)
* **PPO:** 0.95 (Positive, suggesting upward momentum)
* **20-day Relative Divergence Change:** +1.0 (Short-term upward trend)
* **Expected Return (Long-term):** 99.1%  This indicates a significant potential for outperformance relative to the S&P 500 over a long-term (2+ years) investment horizon, assuming the current trend continues.  However, it's crucial to remember that this is a forecast and subject to considerable uncertainty.


**4. Recent Earnings Analysis:**

The company has reported consistent net losses over the provided period.  While revenue has shown some growth, the negative EPS and lack of profitability raise concerns.  Further investigation into the reasons for losses is needed.


| Date       | EPS   | Revenue     |
|------------|-------|-------------|
| 2024-11-12 | -0.26 | $0.44 B     |
| 2024-08-09 | -0.3  | $0.41 B     |
| 2024-05-10 | -0.56 | $0.37 B     |
| 2023-11-09 | -0.95 | $0.27 B     |
| 2024-11-12 | -0.95 | $0.27 B     |


**5. Financial Information:**

The financial data shows increasing revenue, but also reveals negative Return on Equity (ROE), indicating the company is not generating sufficient returns on its shareholder's investments.  While profit margins are relatively high, the negative ROE is a major concern and warrants further investigation into the company's capital allocation and operational efficiency.


**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|----------|---------------|
| 2024-12-31 | $0.48B  | 62.94%        |
| 2024-09-30 | $0.44B  | 61.79%        |
| 2024-06-30 | $0.41B  | 58.83%        |
| 2024-03-31 | $0.37B  | 56.72%        |
| 2023-12-31 | $0.31B  | 51.38%        |


**Capital and Profitability:**

| Quarter    | Equity  | ROE    |
|------------|---------|--------|
| 2024-12-31 | $1.20B | -4.50% |
| 2024-09-30 | $0.88B | -3.60% |
| 2024-06-30 | $0.84B | -4.48% |
| 2024-03-31 | $0.79B | -8.51% |
| 2023-12-31 | $0.77B | -10.20%|


**6. Overall Analysis:**

NTRA has shown significant historical outperformance compared to the S&P 500, but this comes with considerable volatility and risk.  While recent price movements suggest short-term upward momentum, the negative EPS and ROE raise serious concerns about the company's long-term sustainability.  The high expected return is based on historical data and does not guarantee future performance.  A thorough fundamental analysis, including a deeper dive into the reasons for the losses and the sustainability of revenue growth, is necessary before making any investment decisions.  Investors should carefully consider the high risk involved.  The high profit margins are partially offset by the negative ROE, which needs further examination.  The high volatility, as shown by the Maximum Drawdown (MDD), should not be overlooked.
